Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.09
- Piotroski Score 5.00
- Grade Buy
- Symbol (PBYI)
- Company Puma Biotechnology, Inc.
- Price $3.00
- Changes Percentage (3.28%)
- Change $0.1
- Day Low $2.89
- Day High $3.14
- Year High $7.73
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.32
- Trailing P/E Ratio 11.02
- Forward P/E Ratio 11.02
- P/E Growth 11.02
- Net Income $21.59 M
Income Statement
Quarterly
Annual
Latest News of PBYI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
With A Return On Equity Of 18%, Has Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Management Done Well?
Return on Equity (ROE) measures a company's profit generation from shareholder investments. Puma Biotechnology's ROE of 18% is respectable, but its high debt level raises risks. ROE is a key indicator...
By Yahoo! Finance | 1 month ago -
Puma Biotechnology (NASDAQ:PBYI) investors are sitting on a loss of 79% if they invested five years ago
Puma Biotechnology, Inc. (NASDAQ:PBYI) saw a 79% drop in share price over five years. Despite recent profitability, revenue decline raises concerns about long-term growth. Investors should analyze com...
By Yahoo! Finance | 2 months ago -
Analysts Have Been Trimming Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target After Its Latest Report
Puma Biotechnology exceeded market expectations in its recent quarterly results, with revenues beating forecasts by 5.4%. Analysts anticipate a 43% increase in earnings per share for 2024, showing imp...
By Yahoo! Finance | 3 months ago
